新型阴茎牵引装置Penimaster PRO在稳定期阴茎硬结症中的疗效与安全性:对照多中心研究
该多中心随机对照研究纳入93例稳定期阴茎硬结症患者,47例使用Penimaster PRO牵引装置12周,46例不干预。结果显示牵引组弯曲度平均减少31.2°(改善41.1%),拉伸阴茎长度平均增加1.8 cm,IIEF-EF评分平均改善5分,且弯曲度改善与每日使用时长呈剂量依赖关系。
要点
- Penimaster PRO牵引12周可使稳定期阴茎硬结症弯曲度平均减少31.2°。
- 牵引组拉伸阴茎长度平均增加1.8 cm,IIEF-EF评分平均改善5分。
- 弯曲度改善与每日牵引时长呈剂量依赖,>6 h/天者改善更显著。
核心结论
- Penimaster PRO牵引装置是非侵入性治疗,可使稳定期阴茎硬结症患者弯曲度显著减少、阴茎长度增加及症状改善。
- 建议在行任何矫正手术前,先对稳定期阴茎硬结症患者提供连续3个月的牵引治疗。
研究设计与样本
- 多中心对照研究,共招募93例慢性稳定期阴茎硬结症患者,随机分为Penimaster PRO组(47例)和非干预组(46例),随访12周。
主要发现
- 牵引组12周时弯曲度较基线总体减少31.2°(P < 0.001),相当于基线改善41.1%。
- 牵引组每日使用<4小时者弯曲度减少15°-25°(平均19.7°,改善28.8%;P < 0.05),每日使用>6小时者减少20°-50°(平均38.4°,改善51.4%;P < 0.001)。
- 非干预组弯曲度无显著变化。
- 牵引组拉伸阴茎长度较基线和非干预组显著增加,范围0.5-3.0 cm(平均1.8 cm;P < 0.05)。
- 牵引组IIEF-EF评分平均改善5分;43%患者发生轻度不良事件,如局部不适和龟头麻木。
关键数值与推荐
- 入组标准为慢性稳定期阴茎硬结症,无勃起功能障碍、无明显疼痛、单向弯曲至少45°且稳定>3个月。
- 牵引方案为每日使用装置3-8小时,连续12周,并逐步增加牵引力。
- 主要结局为海绵体内注射前列地尔后完全勃起状态下弯曲度变化,在基线、1、2、3个月评估。
临床怎么用
- 对稳定期阴茎硬结症患者,可在矫正手术前提供连续3个月的Penimaster PRO牵引治疗。
- 牵引效果与每日使用时长相关,每日使用>6小时者弯曲度改善更明显。
- 需告知患者可能出现局部不适和龟头麻木等轻度不良事件。
局限性
- 牵引组41例、非干预组39例完成研究,存在脱落。
- 研究随访时间为12周,未报告更长周期结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the efficacy and safety of a new penile traction device (PTD), 'Penimaster PRO', in a group of patients with stable Peyronie's disease (PD) compared with a non-intervention group in a multicentre study. MATERIAL AND METHODS: A total of 93 patients with chronic stable PD (without erectile dysfunction, with no significant pain, and with a unidirectional curvature of at least 45° being stable for > 3 months) were recruited and followed for a 12-week period. Of these patients, 47 were randomly assigned to the Penimaster PRO group (PG) and 46 to the non-intervention group (NIG). Patients were asked to apply the PTD 3-8 h a day for 12 consecutive weeks, with specific instructions regarding the progressive increase of traction force applied to the penis over time. The primary outcome of the study was the change in the degree of curvature measured in the fully erect state after intracavernosal injection of alprostadil at baseline, 1, 2 and 3 months. Other variables, such as the type of curvature, stretched penile length (SPL), Peyronie's Disease Questionnaire (PDQ) scores, erectile function domain of the International Index of Erectile function (IIEF-EF) score and adverse events (AEs) were also assessed in each visit. RESULTS: Forty-one patients in the PG and 39 in the NIG completed the study. There was an overall reduction in curvature of 31.2° (P < 0.001) at 12 weeks compared to baseline in the PG, representing a 41.1% improvement from baseline, which significantly correlated with the number of daily hours the device was applied in a dose-dependent manner. Those patients using the device < 4 h/day experienced a reduction of 15°-25° (mean 19.7°, 28.8% improvement; P < 0.05), while patients using the device > 6 h/day experienced greater curvature reduction, ranging from 20° to 50° (mean of 38.4°, 51.4% improvement; P < 0.001). In contrast, no significant changes in curvature were observed in the NIG. Furthermore, SPL increased significantly in the PG compared to baseline and compared with the NIG, ranging from 0.5 to 3.0 cm (mean 1.8 cm; P < 0.05). The IIEF-EF score also improved in patients in the PG (by a mean of 5 points). Mild AEs occurred in 43% of patients, such as local discomfort and glans numbness. CONCLUSION: The use of the Penimaster PRO PTD, a non-invasive treatment, should be offered to patients with stable PD for 3 consecutive months before performing any corrective surgery, as this provided a significant reduction in the curvature, an increase in penile length and a significant improvement of the symptoms and bother induced by PD.
引用
- Moncada I, Krishnappa P, Romero J, et al. Penile traction therapy with the new device 'Penimaster PRO' is effective and safe in the stable phase of Peyronie's disease: a controlled multicentre study. BJU Int. 2018. PMID: 30365247. doi:10.1111/bju.14602
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。